EGFR and neoplasm: EGFR-targeted cetuximab or nimotuzumab antibody dependent cellular cytotoxicity (ADCC) and activated NK cells were both shown to induce natural killer (NK)-DC crosstalk, which resulted in DC maturation and EGFR-specific CD8(+) T-cell priming and enhanced anti-tumor effects [121, 122].